CXCR2 and melanoma: We demonstrate that targeted deletion of Cxcr2 in tyrosinase-expressing melanoma precursor cells concurrent with induction of the BrafV600E transgene and loss of Pten expression or induction of NRasQ61R and loss of Ink4a, resulted in a significant reduction of melanoma burden.